Study to investigate the activity of AZD5122 when given as a single dose to healthy male subjects
Study identifier:D2650C00006
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
Study Complete
Official Title
A Phase I, Exploratory Study to Assess the Pharmacokinetics of Single Oral Doses and a Single Intravenous Radiolabelled Microtracer Dose of AZD5122 in Healthy Male Subjects
Medical condition
Healthy
Phase
Phase 1
Healthy volunteers
Yes
Study drug
AZD5122, Placebo
Sex
Male
Actual Enrollment
100
Study type
Interventional
Age
18 Years - 65 Years
Date
Study Start Date: 01 Sept 2009
Primary Completion Date: -
Study Completion Date: 01 Nov 2009
Study design
Allocation: Randomized
Endpoint Classification: Pharmacokinetics/dynamics Study
Intervention Model: Parallel Assignment
Masking: Double Blind
Primary Purpose: Basic Science
Verification:
Verified 01 Nov 2013 by AstraZeneca Pharmaceuticals
Sponsors
AstraZeneca Pharmaceuticals
Collaborators
-
Inclusion and exclusion criteria
Loading...
No locations available
| Arms | Assigned Interventions |
|---|---|
| Experimental: 1 AZD5122 oral suspension (part A and B) | Drug: AZD5122 A single dose of oral suspension |
| Placebo Comparator: 2 Placebo oral suspension (part A) | Drug: Placebo A single dose of oral suspension |
| Experimental: 3 AZD5122 oral and IV infusion (part B) | Drug: AZD5122 A single dose of oral suspension Drug: AZD5122 A single intravenous infusion |
Contacts
Investigators
Principal Investigator
Andrew Sparrow
AstraZeneca Clinical Pharmacology Unit, Queens Medical Centre, Nottingham NG7 2UH
